The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rankin, J.
Right arrow Articles by Morley, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rankin, J.
Right arrow Articles by Morley, B. J.
The Journal of Immunology, 2007, 178: 4395-4401.
Copyright © 2007 by The American Association of Immunologists, Inc.

The Bxs6 Locus of BXSB Mice Is Sufficient for High-Level Expression of gp70 and the Production of gp70 Immune Complexes1

Joanna Rankin*, Joseph J. Boyle{ddagger}, S. Jane Rose*, Luisa Gabriel*, Margarita Lewis*, Vasuky Thiruudaian*, Nicola J. Rogers{dagger}, Shozo Izui§ and Bernard J. Morley2,*

* Rheumatology Section, {dagger} Immunology Department, and {ddagger} Histopathology Department, Imperial College, London, United Kingdom; and § Department of Pathology and Immunology, Centre Médical Universitaire, Geneva, Switzerland


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
High levels of the retroviral envelope protein gp70 and gp70 immune complexes have been linked to a single locus on chromosome 13 (Bxs6) in the BXSB model, to which linkage of nephritis was also seen. Congenic lines containing the BXSB Bxs6 interval on a non-autoimmune C57BL/10 background were bred in the presence or absence of the BXSB Y chromosome autoimmune accelerator gene (Yaa), which accelerates disease in male mice. In these mice, we have shown that Bxs6 is sufficient to cause high-level expression of gp70 and the production of gp70 autoantibodies, independently of Yaa, with gp70 immune complex levels enhanced by Yaa. In the presence of Yaa, Bxs6 also causes mild nephritis, and interestingly the sporadic production of high levels of anti-DNA Abs in some mice. Fine mapping using rare recombinant mice suggested that Bxs6 lies between 59.7 and 74.8 megabases (Mb), although the interval of 0.6 Mb between 73.6 and 78.6 Mb on chromosome 13 cannot be excluded in this study.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The BXSB murine strain develops a range of autoantibodies to nuclear components and the severe glomerulonephritis characteristic of human systemic lupus erythematosus (SLE)3 (1). Present in this strain is the Y chromosome autoimmune accelerator gene, Yaa, which accelerates disease in male mice (2, 3, 4). Recently, it has been shown that B10.Yaa congenic mice develop elevated levels of anti-nuclear Abs (ANA), anti-chromatin Abs, and splenomegaly, implying that Yaa is capable of breaking tolerance (5).

In common with other lupus-prone strains, BXSB mice develop gp70 immune complexes (gp70IC) in addition to ANAs (1). gp70 is an endogenous retroviral envelope protein that is present at a low level in the serum of all murine strains. However, in SLE-prone strains gp70 is expressed at a high level and anti-gp70 Abs are produced. gp70IC are subsequently formed, and there are several lines of evidence implicating these complexes in the glomerulonephritis characteristic of these mice (1, 6, 7, 8).

Analysis of the constituents of gp70IC from SLE-prone mice has shown that the gp70 present is most similar to the New Zealand Black (NZB) xenotropic virus envelope protein (9). This is the same type of gp70 found free in the serum of both SLE-prone and non-autoimmune mice (10). The implication is, therefore, that autoimmune mice have an abnormal response to, rather than an abnormal, gp70 protein. Indeed, there are several non-autoimmune strains of mice that produce high levels of gp70, equal to those of SLE-prone mice, but do not develop gp70IC (11).

Linkage studies have been conducted to map the gp70 phenotype and several loci have been identified. Linkage to some of these loci is observed in multiple strains, whereas other loci are strain or cross specific. Linkage has most consistently been seen to the MHC on chromosome 17, and to loci on chromosomes 4, 7, 12, and 13. In crosses with the NZB and New Zealand White (NZW) parental strains of the autoimmune (NZB x NZW)F1 strain, gp70IC levels were linked to the MHC on chromosome 17 (8, 12) and to a locus on chromosome 7 (13). Crosses with these strains have also shown linkage of gp70 levels to chromosome 4 (14, 15). Furthermore, in crosses with the NZB strain, both gp70 and gp70IC levels were linked to chromosome 13 (8, 16). This region on chromosome 13 was also linked to gp70 levels in crosses with the NZW strain, with a trend toward linkage to gp70IC levels (Sgp3) (13). It would therefore appear to be the case that multiple loci from both NZB and NZW mice are involved in the gp70 and gp70IC phenotype observed in the autoimmune F1 strain. Conversely, in the BXSB strain, linkage to high-level expression of gp70 and production of gp70IC has been found to a single locus on chromosome 13 (Bxs6; linkage peak at D13Mit253), to which nephritis was also linked (17). This locus lies in the same region as the NZW and NZB locus described above (Sgp3).

The Bxs6 locus provides a simple system for the study of autoantigen-mediated autoantibody production. In this study, we describe the phenotype of congenic lines containing the BXSB Bxs6 locus on a non-autoimmune B10 background. In addition, we demonstrate fine mapping of the Bxs6 region using recombinant mice and single nucleotide polymorphism (SNP) typing.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Mice

Mice were bred and maintained under identical conditions, disease pathogen free, at Imperial College London. BXSB mice were originally purchased from The Jackson Laboratory, and C57BL/10 (B10) mice were obtained from Harlan Olac. BXSB long-lived (BXSB/ll) mice have been maintained in both Geneva and Imperial College. All congenic strains were bred using a speed congenic approach (18), with microsatellite marker typing at each generation, and fixed by brother-sister mating. B10.YBXSB.BXSB-Chr13 (B10.Yaa.Chr13) congenic mice were bred through multiple backcrosses of (B10 x BXSB)F1 males to B10 females. B10.YBXSB.BXSB-Bxs6 (B10.Yaa.Bxs6) congenic mice were bred through crosses between B10.Yaa.Chr13 congenic mice and B10 mice. B10.BXSB-Chr13 (B10.Chr13) and B10.BXSB-Bxs6 (B10.Bxs6) congenic mice were bred by creating an F1 between male B10 mice and female B10.Yaa.Chr13 or B10.Bxs6.Yaa mice, respectively. The resulting male F1 mice were then crossed back to female B10.Yaa.Chr13 or B10.Yaa.Bxs6 mice, respectively. All B10.Yaa and BXSB control data are from male mice.

Fine mapping of the Bxs6 locus

BXSB x (B10 x BXSB)F1 mice were genotyped with microsatellite markers across the Bxs6 region, and serum gp70 and gp70IC levels were measured at 8 or 12 mo of age for recombinant mapping. SNP data was obtained from www.well.ox.ac.uk/mouse/INBREDS. The genotypes of C57BL/6 (B6), SB/Le, BXSB, and BXSB/ll mice were compared at each SNP to determine which regions of the BXSB/ll strain were derived from B6 and which from BXSB mice.

Serological analyses

As previously described, levels of ANA were measured by indirect immunofluorescence using Hep-2 cells and a FITC-conjugated IgG Fc-specific anti-mouse Ab (5). Levels of gp70 and gp70IC were measured by ELISA as published (19). Anti-dsDNA Abs and anti-ssDNA Abs were measured by ELISA as described previously (5).

Autopsy analyses

Mice were sacrificed at 9, 10, or 12 mo of age. Kidneys were removed into 10% formalin solution, sectioned, and H&E stained. As previously described, kidney sections were scored under a light microscope according to the degree of hypercellularity and mesangial matrix increase of glomeruli. A scale of 0–4 was used, where 0 equaled no histological abnormality, 1 equaled <25%, 2 equaled 25–50%, 3 equaled 51–90%, and 4 equaled >90% of the glomeruli were abnormal (5).

Statistical analysis

All statistical analysis was conducted using GraphPad Prism (version 3.00 for Windows). A two-tailed unpaired t test, Mann-Whitney U test, log-rank test, or two-way ANOVA was used to test for statistical significance of data between cohorts of mice. Statistical tests used for each group of data are described in the figure legends. If p < 0.05, the means were considered to be significantly different.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Breeding of congenic strains containing the BXSB Bxs6 locus

Four congenic strains were bred using a speed congenic approach (18), and for each generation of breeding, mice were selected by typing with a total of 17 microsatellite markers the only markers that distinguish between BXSB and B10 on chromosome 13 (www.ensembl.org/Mus_musculus/index.html). In addition, for the first two generations of the backcross, microsatellites were used to exclude other chromosomes, at least five per chromosome (20, 21), with 25 on chromosome 1 (5), to ensure other Bxs loci were not present in the congenics. B10.Yaa.Chr13 and B10.Chr13 mice were BXSB between microsatellite markers D13Mit3 (19.79 megabases (Mb)) and D13Mit78 (115.80 Mb), which are the markers closest to either end of the chromosome (Fig. 1). B10.Yaa.Bxs6 and B10.Bxs6 mice were BXSB between D13Mit122 (58.99 Mb) and D13Mit233 (80.23 Mb) (Fig. 1). B10.Yaa.Chr13 and B10.Yaa.Bxs6 mice were Yaa positive and B10.Chr13 and B10.Bxs6 mice were Yaa negative. In all studies, Bxs6 congenic mice and Chr13 congenic mice were indistinguishable, and therefore only data for Chr13 congenic mice are shown.


Figure 1
View larger version (19K):
[in this window]
[in a new window]

 
FIGURE 1. Schematic of B10.Chr13.Yaa, B10.Chr13, B10.Bxs6.Yaa, and B10.Bxs6 congenic lines. Diagram showing the BXSB regions included within the B10.Yaa.Chr13, B10.Chr13, B10.Yaa.Bxs6, and B10.Bxs6 congenic lines relative to chromosome 13. The line to the left of the diagram shows chromosome 13, with Mb positions on the left and selected microsatellite markers on the right. Bars indicate the BXSB regions included within the congenic lines, with black sections showing those that are definitively BXSB, and diagonally shaded regions showing those which cannot be defined as B10 or BXSB.

 
The Bxs6 locus caused high-level expression of gp70 and production of gp70IC

B10.Yaa.Chr13 mice had significantly higher levels of gp70 than B10.Yaa mice at 9 mo (p < 0.0001) (Fig. 2a), although levels were still lower than in 6-mo-old BXSB mice (median titer, 31.06 µg/ml; p < 0.0001) (data not shown). B10.Chr13 (p < 0.0001) also had significantly higher levels of gp70 than B10.Yaa mice, as did female B10.Yaa.Chr13 mice (p < 0.0001). However, the level of gp70 was significantly lower in female B10.Yaa.Chr13 mice than in male B10.Yaa.Chr13 (p < 0.0001) and male B10.Chr13 (p < 0.0001) mice.


Figure 2
View larger version (16K):
[in this window]
[in a new window]

 
FIGURE 2. Serum gp70 and gp70IC levels, survival, and histology in congenic and control mice. Serum gp70 (a) and gp70IC (b) levels in B10.Yaa, B10.Yaa.Chr13, B10.Chr13, and female B10.Yaa.Chr13 mice. All mice were measured at 9 mo of age. Each symbol depicts an individual mouse and horizontal lines show the median value for each group. Statistical significance of the difference of each strain from the B10.Yaa control was determined by an unpaired t test and significant p values are illustrated (***, p < 0.0001; *, p < 0.05), and interactions controlling phenotypes were compared using a two-way ANOVA and are described in Results. c, Kaplan-Meier survival curves of congenic and control mice. Twenty-four mice were followed until 12 mo of age for the B10.Yaa.Chr13 ({blacksquare}) and B10.Chr13 (•) strains, and 10 mice were followed until 12 mo of age for the B10.Yaa strain ({blacktriangledown}). Statistical significance of each strain from the B10.Yaa control was determined by a log-rank test with one degree of freedom, and significant p values are shown. d, Histology gradings in B10.Yaa, male B10.Yaa.Chr13, B10.Chr13, and female B10.Yaa.Chr13 mice. All mice were measured at 12 mo of age. Each symbol depicts an individual mouse and horizontal lines show the median value for each group. Data for B10.Yaa mice are published previously (5 ).

 
B10.Yaa.Chr13 congenic mice had significantly higher levels of gp70IC than B10.Yaa mice at 9 mo (p < 0.0001) (Fig. 2b), but levels were still lower than those of 6-mo-old BXSB mice (median titer, 6.0 µg/ml; p < 0.0001) (data not shown). B10.Chr13 congenic mice also had significantly higher levels of gp70IC than B10.Yaa mice (p = 0.0001), although significantly lower than those of male B10.Yaa.Chr13 mice (p = 0.0001). The level of gp70IC was not significantly different between B10.Chr13 and female B10.Yaa.Chr13 mice. A correlation was observed between gp70 and gp70IC levels (r = 0.4032, p = 0.0411 at 9 mo), which corroborates previously published data (17).

There is significant interaction between the Chr 13 locus and Yaa in the production of gp70 (p < 0.0001) and gp70IC (p = 0.0038) as determined by a two-way ANOVA.

The Bxs6 locus accelerated mortality

B10.Yaa.Chr13 mice had a marginally significant decrease in survival rate compared with B10.Yaa mice (p = 0.0387) (Fig. 2c). Mortality in B10.Yaa.Chr13 mice was 17% (4 of 24), as opposed to 0% (0 of 24) in B10.Yaa mice at 12 mo. Mortality in the B10.Chr13 strain was not significantly different to that of the B10.Yaa strain.

The Bxs6 locus caused increased incidence and severity of nephritis

B10.Yaa mice had nephritis grades between 0 and 1, which can thus be considered normal. Grade 2 therefore indicates a mild degree of nephritis, grade 3 a significant degree of nephritis, and grade 4 severe nephritis as seen in the BXSB parental strain (20). Of the B10.Yaa.Chr13 mice measured, 15% (3 of 20) developed mild nephritis and 10% (2 of 20) significant nephritis (Fig. 2d). For the female B10.Yaa.Chr13 mice, 0% (0 of 7) had a grade above 1, and for the B10.Chr13 congenic mice 0% (0 of 21) had a grade above 0.

The Bxs6 locus caused elevated levels of autoantibodies to nuclear components

It has previously been shown that B10.Yaa mice have higher spleen weights than B10 mice (5). B10.Yaa.Chr13 congenic mice had significantly larger spleens than B10.Yaa (p < 0.0001) mice at 12 mo (Fig. 3a). However, spleens from B10.Chr13 and female B10.Chr13.Yaa mice were not significantly different from the spleens of B10.Yaa mice.


Figure 3
View larger version (17K):
[in this window]
[in a new window]

 
FIGURE 3. Spleen weights and levels of Abs to nuclear components in congenic and control mice. Spleen weights (a), ANA titers (b), anti-ssDNA Ab levels (c), and anti-dsDNA Ab levels (d) in B10.Yaa, male B10.Yaa.Chr13, B10.Chr13, and female B10.Yaa.Chr13 mice. Mice were measured at 9 or 10 mo (b–d), or 12 mo of age (a). Each symbol depicts an individual mouse and horizontal lines show the median value for each group. ANA and splenomegaly data for B10.Yaa mice are published previously (24 ). Statistical significance of the difference of each strain from the B10.Yaa control was determined by an unpaired t test (a) or a Mann-Whitney U test (b–d), and significant p values are illustrated (***, p < 0.0001; *, p < 0.05). Interactions controlling phenotypes were compared using a two-way ANOVA and are described in Results.

 
It has also previously been shown that B10.Yaa congenic mice develop elevated levels of ANA compared with B10 mice (5). Our data showed that B10.Yaa.Chr13 congenic mice had significantly higher levels of ANA than B10.Yaa mice at 9 mo (p = 0.0001) (Fig. 3b). Furthermore, B10.Chr13 mice had significantly higher levels of ANA than B10 mice (p = 0.0236) (data not shown), although significantly lower levels of ANA than B10.Yaa mice (p = 0.0126). There was no significant difference between B10.Chr13 and female B10.Chr13.Yaa mice. A correlation was observed between ANA levels and gp70IC levels at 9 mo (r = 0.4299 and p = 0.0406).

There is significant interaction between the Chr 13 locus and Yaa in the production of splenomegaly and ANA (p < 0.0001) as determined by a two-way ANOVA.

No linkage of anti-DNA Abs had previously been found to the Bxs6 locus. Indeed, B10.Yaa.Chr13 mice and B10.Yaa mice did not have significantly different levels of anti-ssDNA Abs at 9 mo (Fig. 3c). However, although not statistically significant, there was clearly an upward trend observed for B10.Yaa.Chr13 mice. None of the B10.Yaa mice developed detectable levels of anti-ssDNA Abs (<39 ELISA units) at any time point, but for serially tested B10.Yaa.Chr13 mice, 6 mice of 23 (26%) developed detectable levels of anti-ssDNA Abs (>39 ELISA units) for at least one time point. Indeed, five of these mice, and thus 22% of the total, developed high levels of above 100 ELISA units. It would therefore appear that it is possible for occasional congenic mice to develop high levels of anti-ssDNA Abs.

B10.Yaa.Chr13 mice also did not have significantly different levels of anti-dsDNA Abs to B10.Yaa mice at 9 mo (Fig. 3d). Interestingly, however, a subset of B10.Yaa.Chr13 mice developed high levels of anti-dsDNA Abs. All of the B10.Yaa mice tested had undetectable levels of anti-dsDNA Abs (<250 ELISA units) at all time points, but for serially tested B10.Yaa.Chr13 mice, 10 of the 23 measured (43%) developed detectable levels of anti-dsDNA Abs for at least one time point. Indeed, three of these mice, and hence 13% of the total, developed very high levels of anti-dsDNA Abs of above 1,000 ELISA units.

A highly significant correlation was observed between the production of anti-ssDNA Abs and anti-dsDNA Abs at 12 mo (r = 0.9160 and p < 0.0001). It was generally found that it was the same mice that had high levels of anti-ssDNA Abs and anti-dsDNA Abs. Thus, the mouse shown in Fig. 3c, with the highest level of anti-ssDNA Abs (276 ELISA units) is the same as the mouse shown in Fig. 3d, with the highest level of anti-dsDNA Abs (5748 ELISA units).

The Bxs6 locus can be mapped to a total region of 15.7 Mb

Recombinant mapping was conducted using BXSB x (B10 x BXSB)F1 backcross mice. On measuring gp70 levels in 45 Bxs6 homozygous (BXSB and Chr13 consomic) mice and 11 heterozygous (F1) mice at 8 mo of age, it was determined that only Bxs6 heterozygous mice had levels of gp70 below 9.3 µg/ml (data not shown). For the backcross mice, we had previously demonstrated that for gp70 in 92 homozygotes and 59 heterozygotes at 12 mo of age, only Bxs6 heterozygous mice were found to have levels below 2.6 µg/ml (17). Therefore, any recombinant mice with gp70 titers below these levels (at the respective age points) could be assumed to be heterozygous for Bxs6. Two such mice (13.10 and 8.78) were identified as having informative recombinations. Mouse 13.10 had a gp70 level of 4.4 µg/ml, measured at 8 mo of age. Mouse 8.78 had a gp70 level of 1.3 µg/ml, measured at 12 mo of age. Thus, both were defined as low producers of gp70. Through the exclusion of any homozygous regions, these two mice narrowed down the Bxs6 locus from the 35 Mb identified by the linkage analysis, to the 18.9 Mb region between 59.7 and 78.6 Mb (Fig. 4a).


Figure 4
View larger version (23K):
[in this window]
[in a new window]

 
FIGURE 4. Fine mapping of the Bxs6 locus. a, Data for BXSB x (B10 x BXSB) recombinant mice with low levels of gp70 and gp70IC that narrow down the Bxs6 region. Microsatellite markers are given at the top, in the order of 5' to 3' from left to right, with gaps containing no informative markers shown by // and the size of the gap. {blacksquare}, Indicate that mice were B10/BXSB heterozygous for that marker; {square}, indicate that mice were BXSB homozygous for that marker; and squares with a diagonal line through them are unknown genotypes. The particular mice with the genotype shown are given on the right, and the Bxs6 region as defined by these two mice, from 59.7 to 78.6Mb, is shown below. b, SNP map of the Bxs6 locus, with horizontal bars depicting the genome of either BXSB or BXSB/ll mice. SNPs were studied every 100–200 kb on average and only informative SNPs are illustrated (www.well.ox.ac.uk/mouse/INBREDS). Black blocks show that a region is of SB/Le origin, gray blocks show that a region is of B6 origin, and white blocks show that the origin is unknown, as defined by SNP genotyping. The position on chromosome 13 in Mb is given on the scale above. Also labeled are discrete sections of the genome: A depicts the region of the genome in which BXSB and BXSB/ll mice have the same genotype, and B depicts the region in which BXSB and BXSB/ll mice differ in genotype.

 
In addition to this approach, the recently published SNP map of the mouse genome (www.well.ox.ac.uk/mouse/INBREDS), with SNPs at every 10 kb, was used to define regions of the Bxs6 locus that could be excluded. The BXSB/ll strain is an alternative recombinant inbred strain derived from SB/Le and B6 mice (M. E. Haywood, L. Gabriel, S. J. Rose, N. J. Rogers, S. Izui, B. J. Morley, manuscript submitted for publication), but does not have the early mortality seen in BXSB mice. Interestingly, however, the BXSB/ll strain does develop significantly elevated levels of gp70 compared with B10.Yaa mice (p = 0.0065; data not shown), although levels are not as high as those seen in BXSB mice. It can therefore be assumed that the Bxs6 locus will map to intervals that were inherited from the same parental stock in BXSB and BXSB/ll mice. Hence, by comparison of the genotype of BXSB and BXSB/ll mice using the SNP map, regions of the Bxs6 locus could be eliminated.

Using the genotype of B6, SB/Le, BXSB, and BXSB/ll mice at each SNP as published, two discrete sections within the Bxs6 locus could be identified, as labeled in Fig. 4b. In Fig. 4b, section A (59.7–74.5 Mb), the BXSB/ll and BXSB both originate from SB/Le. In Fig. 4b, section B (74.8–78.0 Mb), BXSB/ll and BXSB differ in their origins with BXSB/ll from SB/Le and BXSB from B6. There are, however, three SNPs in section B that suggest an SB/Le origin for BXSB in this region and therefore indicate some heterogeneity for this interval, or some further mutation.

In Fig. 4b, section A, there are 47 SNPs that are informative between B6 and SB/Le of a total of 69, in a region of 14.8 Mb. The largest gap within this region with no informative markers is 1.4 Mb, but 80% of this section is within 0.5 Mb of an informative marker. For Fig. 4b, section B, there are 18 SNPs that are informative between B6 and SB/Le of a total of 22, in a region of 3.2 Mb. The largest gap within this region with no informative markers is 0.9 Mb, but 90% of this section is within 0.5 Mb of an informative marker.

Assuming that Fig. 4b, section B, between 74.8 and 78.0 Mb, can be eliminated from the Bxs6 region as BXSB/ll and BXSB differ in this region, the interval can be narrowed down to the 15.1 Mb between 59.7 and 74.8 Mb, although the 0.6 Mb from 78.0 to 78.6 Mb cannot be excluded, a combined region of 15.7 Mb.


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
From the data presented in this study, a model can be suggested for the role of Bxs6 and its interaction with the Yaa locus, as summarized in Fig. 5. First, Bxs6 causes the production of high levels of gp70, and Yaa is not involved in this process. However, the levels of gp70 are not as high as those seen in the BXSB strain, thus showing that there must be other contributory factors in the BXSB genome.


Figure 5
View larger version (12K):
[in this window]
[in a new window]

 
FIGURE 5. Model of the Bxs6 phenotype. Model of the phenotype obtained by Bxs6 alone (left of central line), and by Bxs6 in the presence of Yaa (right of central line). Arrows depict the most likely sequence of events leading to the phenotypes shown. Also indicated is whether phenotypes are developed at a low level (single line boxes) or at a high level (double line boxes). Shown on the right side is a summary of the effect of Yaa on the phenotypes shown.

 
Interestingly, the female B10.Chr13.Yaa mice, although they also had high levels of gp70, only had levels approximately half that of corresponding Yaa-negative or -positive congenic male mice. It would therefore seem that there is a gender effect for levels of gp70. This effect could be due to hormonal influences, but could also be due to genes within the Bxs6 locus that regulate the expression of proteins in a sex-dependent manner.

The high levels of gp70 appear to result in the production of anti-gp70 Abs and therefore the development of gp70IC. Thus, high-level autoantigen titer in this model does direct the production of autoantibodies as previously reported (17). However, the production of gp70IC is not solely dependant on high levels of gp70, because levels are accelerated by the presence of Yaa. This result is consistent with the finding that certain non-autoimmune strains develop high levels of gp70, equal to those of SLE-prone strains, but do not produce gp70IC (11). It can therefore be hypothesized that Yaa provides a further break in tolerance above that caused by Bxs6 alone, allowing higher levels of gp70IC to be produced. It has been proposed that the acceleration of disease can be attributed to a duplication of Tlr7 on the Y chromosome of Yaa-bearing mice (22, 23). TLR7 is one of four nucleic acid-sensing Toll receptors, specifically recognizing ssRNA. Although this process provides no direct link to the enhancement of Bxs6-driven gp70IC production by Yaa, triggering of TLR7 is known to stimulate the production of large amounts of proinflammatory cytokines. These include IFN-{alpha}, which has been shown to enhance Ag presentation capacity of both B cells and dendritic cells driving T cell development and activation, as well as B cell hyperresponsiveness and increased deposition of immune complexes in the glomeruli (24).

Even in the presence of Yaa, the level of gp70IC caused by Bxs6 in the congenic mice is significantly lower than that seen in BXSB mice. Therefore, there must be further factors in the BXSB genome that have an effect on the production of gp70IC. One such example is the interval Gp1 on chromosome 9,which was identified by linkage analysis in Bxs6 homozygotes as an additional locus that contributed to gp70IC levels (17).

A proportion of the B10.Chr13 mice developed elevated levels of ANA even in the absence of Yaa, therefore showing that Bxs6 is sufficient for ANA production. However, the Bxs6 locus was not able to cause high levels of anti-DNA Abs alone, implying that Yaa provided a necessary further break in tolerance.

A number of B10.Yaa.Chr13 mice produced high-titer anti-ssDNA and anti-dsDNA Abs. It has been demonstrated that, in addition to anti-gp70 Abs, Abs to nuclear material can also bind to NZB xenotropic retroviruses (14), due to the presence of this material on the surface of the retrovirus. The correlation between gp70IC and ANA levels, consistent with both phenotypes being reliant on high levels of gp70, provides support for this theory.

Our data has also shown that Bxs6 can cause mild nephritis in the presence of Yaa. There was no correlation observed between the level of nephritis and any other traits. However, the likelihood is that the observed nephritis is caused by the presence of gp70IC, because levels of gp70IC correlated most strongly with nephritis in the BXSB backcross studied for the linkage analysis (17). Indeed, there is substantial evidence for the involvement of gp70IC in the development of nephritis. It has been shown that gp70IC is deposited in the kidneys of SLE-prone mice (1), and in many crosses of autoimmune mice levels of gp70IC are significantly correlated with nephritis (6, 7, 8). However, the data presented in this study demonstrate that Bxs6 cannot cause the development of nephritis in the absence of Yaa, possibly due to the reduction in gp70IC.

Fine mapping of the Bxs6 locus using recombinant BXSB x (B10 x BXSB)F1 backcross mice suggested that Bxs6 lies in the 18.9 Mb between 59.7 and 78.6 Mb on chromosome 13. Although this result is based on the genotype of only two mice with low levels of gp70 and gp70IC, our studies have demonstrated that mice with low levels such as these are reliably heterozygous for Bxs6. To extend these mapping data, we used the recently available SNP database, which enabled us to eliminate a further region in which the Bxs6 gene is unlikely to lie. This assumption could be made because BXSB/ll and BXSB mice are genotypically different in this region, which would not be expected at the Bxs6 locus as both strains develop elevated levels of gp70. The entire region from 74.8–78.0 Mb (Fig. 4b, section B) could therefore be eliminated. Based on this assumption, the Bxs6 region can be narrowed down to the 15.1 Mb between 59.7 and 74.8 Mb, and the 0.6 Mb between 78.0 and 78.6 Mb on chromosome 13, which is a total region of 15.7 Mb.

Congenic lines have been bred containing the NZW Sgp3 locus, which lies in the same region as the Bxs6 locus, on a B6 background (25). The Sgp3 locus was identified in a B6 x (NZW x B6.Yaa)F1 backcross as linked to gp70, with a trend toward linkage to gp70IC. Like the Bxs6 locus, there was no linkage to anti-DNA Abs. The Sgp3 locus was mapped to between D13Mit142 (60.7 Mb) and D13Mit254 (76.5 Mb) on chromosome 13 using overlapping congenic strains, which is an interval of 15.8 Mb. The gp70 phenotype of Bxs6 and Sgp3 congenic mice is very similar. This similarity suggests that it is most likely the same gene for both Sgp3 and Bxs6 that controls levels of gp70. The largest of the two regions that comprise the 15.7 Mb now suggested for the Bxs6 locus is predominantly contained within the region identified for the Sgp3 gene. It is therefore highly likely that, given the similarity between the effects of Bxs6 and Sgp3, the 0.6 Mb interval between 78.0 and 78.6 Mb can be eliminated and the gene mapped to a 14.1 Mb interval between 60.7 and 74.8 Mb.

Also mapped to the same interval (56.6–77.5 Mb) is Gv1 (26), which, along with the gene Gv2, is required for the expression of GIX, an antigenic determinant of gp70, on normal lymphoid cells (27, 28). Gv1 encodes a trans-acting factor, which regulates retroviral expression but has not been cloned. However, functionally and genetically, it is a very strong candidate and it is likely that Bxs6, Sgp3, and Gv1 are the same locus.

Interestingly, the Sgp3 congenic mice did not produce gp70IC, despite having equally high levels of gp70 as the Bxs6 congenic mice. It is therefore feasible that the Bxs6 locus contains a second gene that causes the development of gp70IC, which is not present in the Sgp3 locus. Although a B10 locus has been identified as important in gp70IC production (29), this locus is BXSB in the B10.Chr13.Yaa mice and so is not a contributory factor. It may thus be the case that high levels of gp70 allow the production of gp70IC, but that a further factor within the Bxs6 locus is required, but not sufficient, for production to occur. This possibility is under investigation.


    Disclosures
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The authors have no financial conflict of interest.


    Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by grants from the Arthritis Research Campaign (U.K.; to B.J.M.) and the Swiss National Foundation for Scientific Research (to S.I.). Back

2 Address correspondence and reprint requests to Dr. Bernard J. Morley, Rheumatology Section, Faculty of Medicine, Imperial College, Hammersmith Campus, Du Cane Road, London W12 0NN, U.K. E-mail address: b.morley{at}imperial.ac.uk Back

3 Abbreviations used in this paper: SLE, systemic lupus erythematosus; ANA, anti-nuclear Ab; gp70IC, gp 70 immune complex; SNP, single nucleotide polymorphism; Mb, megabase; Yaa, Y chromosome autoimmune accelerator gene. Back

Received for publication September 8, 2006. Accepted for publication December 26, 2006.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Andrews, B. S., R. A. Eisenberg, A. N. Theofilopoulos, S. Izui, C. B. Wilson, P. J. McConahey, E. D. Murphy, J. B. Roths, F. J. Dixon. 1978. Spontaneous murine lupus-like syndromes: clinical and immunopathological manifestations in several strains. J. Exp. Med. 148: 1198-1215. [Abstract/Free Full Text]
  2. Izui, S., N. Ibnou-Zekri, L. Fossati-Jimack, M. Iwamoto. 2000. Lessons from BXSB and related mouse models. Int. Rev. Immunol. 19: 447-472. [Medline]
  3. Pisitkun, P., J. A. Deane, M. J. Difilippantonio, T. Tarasenko, A. B. Satterthwaite, S. Bolland. 2006. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312: 1669-1672. [Abstract/Free Full Text]
  4. Suramanian, S., K. Tus, Q.-Z. Li, A. Wang, X.-H. Tian, J. Zhou, C. Liang, G. Bartov, L. D. McDaniel, X. J. Zhou, et al 2006. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl. Acad. Sci. USA 103: 9970-9975. [Abstract/Free Full Text]
  5. Haywood, M. E., N. J. Rogers, S. J. Rose, J. Boyle, A. McDermott, J. M. Rankin, V. Thiruudaian, M. R. Lewis, L. Fossati-Jimack, S. Izui, et al 2004. Dissection of BXSB lupus phenotype using mice congenic for chromosome 1 demonstrates that separate intervals direct different aspects of disease. J. Immunol. 173: 4277-4285. [Abstract/Free Full Text]
  6. Izui, S., P. J. McConahey, J. P. Clark, L. M. Hang, I. Hara, F. J. Dixon. 1981. Retroviral gp70 immune complexes in NZB x NZW F2 mice with murine lupus nephritis. J. Exp. Med. 154: 517-528. [Abstract/Free Full Text]
  7. Vyse, T. J., C. G. Drake, S. J. Rozzo, E. Roper, S. Izui, B. L. Kotzin. 1996. Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice. J. Clin. Invest. 98: 1762-1772. [Medline]
  8. Tucker, R. M., T. J. Vyse, S. Rozzo, C. L. Roark, S. Izui, B. L. Kotzin. 2000. Genetic control of glycoprotein 70 autoantigen production and its influence on immune complex levels and nephritis in murine lupus. J. Immunol. 165: 1665-1672. [Abstract/Free Full Text]
  9. Izui, S., J. H. Elder, P. J. McConahey, F. J. Dixon. 1981. Identification of retroviral gp70 and anti-gp70 antibodies involved in circulating immune complexes in NZB x NZW mice. J. Exp. Med. 153: 1151-1160. [Abstract/Free Full Text]
  10. Elder, J. H., F. C. Jensen, M. L. Bryant, R. A. Lerner. 1977. Polymorphism of the major envelope glycoprotein (gp70) of murine C-type viruses: virion associated and differentiation antigens encoded by a multi-gene family. Nature 267: 23-28. [Medline]
  11. Izui, S., P. J. McConahey, A. N. Theofilopoulos, F. J. Dixon. 1979. Association of circulating retroviral gp70-anti-gp70 immune complexes with murine systemic lupus erythematosus. J. Exp. Med. 149: 1099-1116. [Abstract/Free Full Text]
  12. Vyse, T. J., S. J. Rozzo, C. G. Drake, S. Izui, B. L. Kotzin. 1997. Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice. J. Immunol. 158: 5566-5574. [Abstract]
  13. Santiago, M. L., C. Mary, D. Parzy, C. Jacquet, X. Montagutelli, R. M. Parkhouse, R. Lemoine, S. Izui, L. Reininger. 1998. Linkage of a major quantitative trait locus to Yaa gene-induced lupus-like nephritis in (NZW x C57BL/6)F1 mice. Eur. J. Immunol. 28: 4257-4267. [Medline]
  14. Tucker, R. M., C. L. Roark, M. L. Santiago-Raber, S. Izui, B. L. Kotzin. 2004. Association between nuclear antigens and endogenous retrovirus in the generation of autoantibody responses in murine lupus. Arthritis Rheum. 50: 3626-3636. [Medline]
  15. Rigby, R. J., S. J. Rozzo, H. Gill, T. Fernandez-Hart, B. J. Morley, S. Izui, B. L. Kotzin, T. J. Vyse. 2004. A novel locus regulates both retroviral glycoprotein 70 and anti-glycoprotein 70 antibody production in New Zealand mice when crossed with BALB/c. J. Immunol. 172: 5078-5085. [Abstract/Free Full Text]
  16. Kikuchi, S., L. Fossati-Jimack, T. Moll, H. Amano, E. Amano, A. Ida, N. Ibnou-Zekri, C. Laporte, M.-L. Santiago-Raber, S. Rozzo, et al 2005. Differential role of three major New Zealand Black-derived loci linked with Yaa-induced murine lupus nephritis. J. Immunol. 174: 1111-1117. [Abstract/Free Full Text]
  17. Haywood, M. E., T. J. Vyse, A. McDermott, E. M. Thompson, A. Ida, M. J. Walport, S. Izui, B. J. Morley. 2001. Autoantigen glycoprotein 70 expression is regulated by a single locus, which acts as a checkpoint for pathogenic anti-glycoprotein 70 autoantibody production and hence for the corresponding development of severe nephritis, in lupus-prone BXSB mice. J. Immunol. 167: 1728-1733. [Abstract/Free Full Text]
  18. Wakeland, E., L. Morel, K. Achey, M. Yui, J. Longmate. 1997. Speed congenics: a classic technique in the fast lane (relatively speaking). Immunol. Today 18: 472-477. [Medline]
  19. Izui, S., G. Lange. 1988. Enzyme-linked immunosorbent assay for detection of retroviral gp70 and gp70-anti-gp70 immune complexes in sera from SLE mice. Clin. Exp. Immunol. 71: 45-49. [Medline]
  20. Haywood, M. E., M. B. Hogarth, J. H. Slingsby, S. J. Rose, P. J. Allen, E. M. Thompson, M. A. Maibaum, P. Chandler, K. A. Davies, E. Simpson, et al 2000. Identification of intervals on chromosomes 1, 3, and 13 linked to the development of lupus in BXSB mice. Arthritis Rheum. 43: 349-355. [Medline]
  21. Hogarth, M. B., J. H. Slingsby, P. J. Allen, E. M. Thompson, P. Chandler, K. A. Davies, E. Simpson, B. J. Morley, M. J. Walport. 1998. Multiple lupus susceptibility loci map to chromosome 1 in BXSB mice. J. Immunol. 161: 2753-2761. [Abstract/Free Full Text]
  22. Pisitkun, P., J. A. Deane, M. J. Difilippantonio, T. Tarasenko, A. B. Satterthwaite, S. Bolland. 2006. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312: 1669-1672. [Abstract/Free Full Text]
  23. Suramanian, S., K. Tus, Q.-Z. Li, A. Wang, X.-H. Tian, J. Zhou, C. Liang, G. Bartov, L. D. McDaniel, X. J. Zhou, et al 2006. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl. Acad. Sci. USA 103: 9970-9975. [Abstract/Free Full Text]
  24. Deane, J. A., S. Bellend. 2006. Nucleic acid-sensing TLRs as modifiers of autoimmunity. J. Immunol. 177: 6573-6578. [Abstract/Free Full Text]
  25. Laporte, C., B. Ballester, C. Mary, S. Izui, L. Reininger. 2003. The Sgp3 locus on mouse chromosome 13 regulates nephritogenic gp70 autoantigen expression and predisposes to autoimmunity. J. Immunol. 171: 3872-3877. [Abstract/Free Full Text]
  26. Oliver, P. L., J. P. Stoye. 1999. Genetic analysis of Gv1, a gene controlling transcription of endogenous murine polytropic proviruses. J. Virol. 73: 8227-8234. [Abstract/Free Full Text]
  27. Stockert, E., L. J. Old, E. A. Boyse. 1971. The G-IX system: a cell surface allo-antigen associated with murine leukemia virus; implications regarding chromosomal integration of the viral genome. J. Exp. Med. 133: 1334-1355. [Abstract]
  28. Tung, J. S., E. S. Vitetta, E. Fleissner, E. A. Boyse. 1975. Biochemical evidence linking the GIX thymocyte surface antigen to the gp69/71 envelope glycoprotein of murine leukemia virus. J. Exp. Med. 141: 198-205. [Abstract/Free Full Text]
  29. Rozzo, S. J., T. J. Vyse, K. Menze, S. Izui, B. L. Kotzin. 2000. Enhanced susceptibility to lupus contributed from the non-autoimmune C57BL/10, but not C57BL/6, genome. J. Immunol. 164: 5515-5521. [Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J. Immunol.Home page
L. Baudino, K. Yoshinobu, N. Morito, S. Kikuchi, L. Fossati-Jimack, B. J. Morley, T. J. Vyse, S. Hirose, T. N. Jorgensen, R. M. Tucker, et al.
Dissection of Genetic Mechanisms Governing the Expression of Serum Retroviral gp70 Implicated in Murine Lupus Nephritis
J. Immunol., August 15, 2008; 181(4): 2846 - 2854.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rankin, J.
Right arrow Articles by Morley, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rankin, J.
Right arrow Articles by Morley, B. J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS